Clindamycin Phosphate
NDC Package 59762-3728-2
Package Information
Clindamycin Phosphate is a medication used to treat acne. Marketed by Mylan Pharmaceuticals Inc., this product is identified by NDC 59762-3728 and is authorized under FDA application NDA050537.
Identification & Billing
- RxCUI: 197519 - clindamycin phosphate 1 % Topical Lotion
- RxCUI: 197519 - clindamycin 10 MG/ML Topical Lotion
- RxCUI: 197519 - clindamycin (as clindamycin phosphate) 1 % Topical Lotion
- RxCUI: 197519 - clindamycin 1 % Topical Lotion
- RxCUI: 2676585 - clindamycin phosphate 1 % Twice-Daily Topical Gel
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59762 - Mylan Pharmaceuticals Inc.
- 59762-3728 - Clindamycin Phosphate
- 59762-3728-2 - 1 BOTTLE in 1 CARTON / 60 mL in 1 BOTTLE
- 59762-3728 - Clindamycin Phosphate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (59762-3728). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59762-3728-2 identifies a specific commercial package of 1 bottle in 1 carton / 60 ml in 1 bottle of Clindamycin Phosphate, labeled by Mylan Pharmaceuticals Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Mylan Pharmaceuticals Inc. on June 20, 1980. The current certification is valid through December 31, 2018.
What are the primary indications for this medication?
This medication is used to treat acne. It helps to decrease the number of acne lesions. Clindamycin is an antibiotic which works by stopping the growth of bacteria.
How is this Mylan Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59762372802. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.